Navigation Links
TGen-led team is 1 of 7 selected for $1 million skin-cancer grants
Date:8/3/2009

PHOENIX, Ariz. Aug. 1, 2009 An international scientific team led by the Translational Genomics Research Institute (TGen) has received a $1 million grant to study skin cancer from the Melanoma Research Alliance.

The grant was made to a team led by Dr. Jeffrey Trent, TGen's President and Research Director, who is the Team Lead among the Principal Investigators in the two-year study: Identification of Novel Melanoma Risk Genes Using High-throughput Genomics.

"The world-wide team of investigators on this project has worked together for a decade to identify individuals and families who are at increased risk for this deadly disease. While the team includes investigators from Europe and Australia, the research is particularly important to Arizonans who are disproportionately affected,'' Dr. Trent said.

Dr. Kevin Brown, an Associate Investigator in TGen's Integrated Cancer Genomics Division, also described the TGen-led team as part of an ongoing collaboration with the International Melanoma Genetics Consortium (GenoMEL), which has identified families worldwide that are predisposed to getting skin cancer.

"There are situations in which there is a strong family history of melanoma. If you can identify the genes, or mutations, that put people at risk for melanoma, you can implement targeted screening or prevention efforts,'' Dr. Brown said.

"Identifying the genes that mediate development of melanoma will give you an understanding of the basic biology, and conceivably could give you some clues into ways that you could do chemo prevention, or other things, for people who are at strong risk of getting melanoma,'' Dr. Brown said.

The other Principal Investigators in the TGen-led research are: Dr. Nicolas Hayward of the Queensland (Australia) Institute of Medical Research; Dr. Goran Jonsson of Lund (Sweden) University; and Dr. Graham Mann of the University of Sydney (Australia).

Arizona's non-Hispanic Caucasian population has among the nation's highest incidence rate of skin cancer. Australia has the highest incidence rate of the disease in the world.

The TGen-led team was one of seven multidisciplinary groups who received a total of $6.9 million in awards June 30 from the Washington, D.C.-based Melanoma Research Alliance (MRA) to pursue novel, outcomes-driven melanoma research.

These awards are part of the MRA's second round of grants focused on research that addresses gaps in translational science. In its second year of grant-making, MRA is now supporting 37 of the most promising melanoma research programs worldwide, totaling more than $16 million (including $6.9 million awarded July 30) in an effort to accelerate progress toward a cure.

"We are energized by the quality of proposals we continue to receive from the melanoma research community. In this latest round of grants, we are pleased to support seven multidisciplinary approaches that hold great potential to advance melanoma treatments," said Dr. Suzanne Topalian, M.D., Chair of the MRA Grant Review Committee and Director of the Johns Hopkins Melanoma Program.

According to the grant description presented by Dr. Trent:

"Early detection of cutaneous malignant melanoma offers the best form of cure. Characterization of the genes influencing melanoma risk is critical towards efforts aimed at disease prevention and early detection.

"Studies of families with multiple melanoma patients have identified mutations in two genes that strongly predispose to the disease, but these mutations are found only in a minority of families.

"To identify additional genes, the International Melanoma Genetics Consortium (GenoMEL) recently completed the largest genetic study of melanoma families to date, comprising 174 families with three or more melanoma patients. This study identified two chromosome positions likely to harbor melanoma susceptibility genes, while a separate smaller study by a GenoMEL member group has identified a third.

"We propose here to extend this collaborative effort by screening all genes at these three chromosomal locations for disease-predisposing mutations in melanoma families. We will also work towards identifying additional susceptibility genes by sequencing the entire genomes of patients from five of the largest melanoma families.

"The identification of novel predisposition genes is a major first step towards accurately estimating individualized disease risk and ultimately implementing disease prevention and early-detection strategies for at-risk individuals. Further, characterization of the molecular mechanisms underlying melanoma susceptibility may lead to a better understanding of the processes underlying melanoma development and progression, and ultimately to novel strategies for melanoma treatment."

The other teams receiving the latest round of MRA grants are:

Developing Melanoma Screening in Primary Care
Principal Investigators:
Team Lead: Martin A. Weinstock, M.D., Ph.D., Rhode Island Hospital and Brown University
Maryam Asgari, M.D., M.P.H., Kaiser Foundation Research Institute
Melody Eide, M.D., M.P.H., Henry Ford Health System
Suzanne Fletcher, M.D., M.Sc., Harvard Pilgrim Health Care and Harvard Medical School
Alan Geller, R.N., M.P.H., Harvard School of Public Health
Allan Halpern, M.D., M.S., Memorial Sloan-Kettering Cancer Center

Manipulating Immune Regulation in Adoptive T-cell Therapy for Melanoma Principal Investigators:
Team Lead: Jeffrey Weber, M.D., Ph.D., H. Lee Moffitt Cancer Center and Research Institute
Patrick Hwu, M.D., M.D. Anderson Cancer Center

Identification and Validation of Combination Therapies for Melanomas
Principal Investigators:
Team Lead: Michael J. Weber, Ph.D., University of Virginia
Levi Garraway, M.D., Ph.D., Dana-Farber Cancer Institute
Dan Gioeli, Ph.D., University of Virginia

Proposal Title: Sequencing of the Melanoma Exome, Transcriptome and Epigenome Principal Investigators:
Team Lead: Ruth Halaban, Ph.D., Yale University
Marcus Bosenberg, M.D., Ph.D., Yale University
Michael Krauthammer, M.D., Ph.D., Yale University
David Stern, Ph.D., Yale University

Combinatorial Immunotherapy for Melanoma with B7-H1/PD-1 Checkpoint Blockade
Principal Investigators:
Team Lead: Drew Pardoll, M.D., Ph.D., Johns Hopkins University
Lieping Chen, M.D., Ph.D., Johns Hopkins University
Suzanne Topalian, M.D., Johns Hopkins University

Identification of Novel Melanoma Risk Genes Using High-throughput Genomics Principal Investigators:
Team Lead: Jeffrey Trent, Ph.D., Translational Genomics Research Institute
Nicolas Hayward, Ph.D., Queensland Institute of Medical Research
Goran Jonsson, Ph.D., Lund University
Graham Mann, Ph.D., The University of Sydney

Defining the Importance of Immunity to NY-ESO-1 in Melanoma
(Co-funded by the Cancer Research Institute)
Principal Investigators:
Team Lead: Jedd D. Wolchok, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center
James P. Allison, Ph.D., Memorial Sloan-Kettering Cancer Center
Jonathan Cebon, Ph.D., Ludwig Institute for Cancer Research
Alexander Eggermont, M.D., Ph.D., Daniel den Hoed Cancer Center
Sacha Gnjatic, Ph.D., Ludwig Institute for Cancer Research
Dirk Jger, M.D., University Hospital Heidelberg
Elke Jger, Ph.D., Goethe University Frankfurt
Alexander Knuth, M.D., University of Zurich
Lloyd J. Old, M.D., Ludwig Institute for Cancer Research


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Brooke Franchise Corporation Announces Selected July Results
2. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
3. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
4. Crdentia Selected by High Rock Raceway to Provide Healthcare Staffing Services
5. Fry Construction Selected for High-Profile Medical Imaging Project
6. Meth Project Advertisements Selected for National Prevention Campaign
7. Eight Graduate Nursing Students Selected to Receive The California Endowment-AACN Minority Nurse Faculty Scholarship
8. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
9. SAIC Selected to Support the U.S. Military Theater Medical Information Program-Joint
10. The Cooper Institutes FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool
11. CBaySystems Selected to Receive Deloittes 2007 Maryland Technology Fast 50 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
(Date:9/18/2017)... , Sept. 18, 2017  PMD Healthcare of ... Pharmacy of Kalamazoo, Mich. , have ... service that expedites and streamlines patient and provider access ... 2.0, and wellness management services.  ... used to measure lung function for a variety of ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
Breaking Medicine Technology: